Cargando…

PARP-1 Val762Ala Polymorphism and Risk of Cancer: A Meta-Analysis Based on 39 Case-Control Studies

BACKGROUND: Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear chromatin-associated enzyme involved in several important cellular processes, particularly in the DNA repair system. PARP-1 rs1136410: C>T is among the most studied polymorphisms and likely involved in human carcinogenesis. However,...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Qin, Lu, Jing, Zhu, Hongcheng, Xu, Liping, Cheng, Hongyan, Zhan, Liangliang, Yang, Xi, Zhang, Chi, Sun, Xinchen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4031170/
https://www.ncbi.nlm.nih.gov/pubmed/24853559
http://dx.doi.org/10.1371/journal.pone.0098022
_version_ 1782317494786064384
author Qin, Qin
Lu, Jing
Zhu, Hongcheng
Xu, Liping
Cheng, Hongyan
Zhan, Liangliang
Yang, Xi
Zhang, Chi
Sun, Xinchen
author_facet Qin, Qin
Lu, Jing
Zhu, Hongcheng
Xu, Liping
Cheng, Hongyan
Zhan, Liangliang
Yang, Xi
Zhang, Chi
Sun, Xinchen
author_sort Qin, Qin
collection PubMed
description BACKGROUND: Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear chromatin-associated enzyme involved in several important cellular processes, particularly in the DNA repair system. PARP-1 rs1136410: C>T is among the most studied polymorphisms and likely involved in human carcinogenesis. However, results from previous studies are inconclusive. Thus, a meta-analysis was conducted to derive a more precise estimation of the effects of this enzyme. METHODOLOGY AND PRINCIPAL FINDINGS: A comprehensive search was conducted in the PubMed and EMBASE databases until December 9, 2013. A total of 39 studies with 16,783 cancer cases and 23,063 control subjects were included in the meta-analysis on the basis of the inclusion and exclusion criteria. No significant association between the PARP-1 Val762Ala polymorphism and cancer risk was found when all of the studies were pooled into the analysis (VA + AA vs. VV: OR = 1.03, 95% CI = 0.95–1.11). The subgroup analysis of cancer types revealed that the –762Ala allele was associated with increased risk of gastric, cervical, and lung cancers and a decreased risk of glioma. In addition, a significantly increased risk of cancer associated with the polymorphism was observed in Asian descendents (VA + AA vs. VV: OR = 1.17, 95% CI = 1.09–1.25; AA vs. VV: OR = 1.28, 95% CI = 1.08–1.51; VA vs. VV: OR = 1.12, 95% CI = 1.04–1.20; AA vs. VA + VV: OR = 1.09, 95% CI = 1.03–1.39). These results also indicated that a joint effect between PARP-1 Val762Ala and XRCC1 Arg399Gln could be involved in the risk of cancer development (OR = 3.53, 95% CI = 1.30–9.59). CONCLUSION: The present meta-analysis provides evidence that the PARP-1 Val762Ala may be involved in cancer development at least in some ethnic groups (Asian) or some specific cancer types (gastric, cervical, and lung cancers, and glioma).
format Online
Article
Text
id pubmed-4031170
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-40311702014-05-28 PARP-1 Val762Ala Polymorphism and Risk of Cancer: A Meta-Analysis Based on 39 Case-Control Studies Qin, Qin Lu, Jing Zhu, Hongcheng Xu, Liping Cheng, Hongyan Zhan, Liangliang Yang, Xi Zhang, Chi Sun, Xinchen PLoS One Research Article BACKGROUND: Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear chromatin-associated enzyme involved in several important cellular processes, particularly in the DNA repair system. PARP-1 rs1136410: C>T is among the most studied polymorphisms and likely involved in human carcinogenesis. However, results from previous studies are inconclusive. Thus, a meta-analysis was conducted to derive a more precise estimation of the effects of this enzyme. METHODOLOGY AND PRINCIPAL FINDINGS: A comprehensive search was conducted in the PubMed and EMBASE databases until December 9, 2013. A total of 39 studies with 16,783 cancer cases and 23,063 control subjects were included in the meta-analysis on the basis of the inclusion and exclusion criteria. No significant association between the PARP-1 Val762Ala polymorphism and cancer risk was found when all of the studies were pooled into the analysis (VA + AA vs. VV: OR = 1.03, 95% CI = 0.95–1.11). The subgroup analysis of cancer types revealed that the –762Ala allele was associated with increased risk of gastric, cervical, and lung cancers and a decreased risk of glioma. In addition, a significantly increased risk of cancer associated with the polymorphism was observed in Asian descendents (VA + AA vs. VV: OR = 1.17, 95% CI = 1.09–1.25; AA vs. VV: OR = 1.28, 95% CI = 1.08–1.51; VA vs. VV: OR = 1.12, 95% CI = 1.04–1.20; AA vs. VA + VV: OR = 1.09, 95% CI = 1.03–1.39). These results also indicated that a joint effect between PARP-1 Val762Ala and XRCC1 Arg399Gln could be involved in the risk of cancer development (OR = 3.53, 95% CI = 1.30–9.59). CONCLUSION: The present meta-analysis provides evidence that the PARP-1 Val762Ala may be involved in cancer development at least in some ethnic groups (Asian) or some specific cancer types (gastric, cervical, and lung cancers, and glioma). Public Library of Science 2014-05-22 /pmc/articles/PMC4031170/ /pubmed/24853559 http://dx.doi.org/10.1371/journal.pone.0098022 Text en © 2014 Qin et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Qin, Qin
Lu, Jing
Zhu, Hongcheng
Xu, Liping
Cheng, Hongyan
Zhan, Liangliang
Yang, Xi
Zhang, Chi
Sun, Xinchen
PARP-1 Val762Ala Polymorphism and Risk of Cancer: A Meta-Analysis Based on 39 Case-Control Studies
title PARP-1 Val762Ala Polymorphism and Risk of Cancer: A Meta-Analysis Based on 39 Case-Control Studies
title_full PARP-1 Val762Ala Polymorphism and Risk of Cancer: A Meta-Analysis Based on 39 Case-Control Studies
title_fullStr PARP-1 Val762Ala Polymorphism and Risk of Cancer: A Meta-Analysis Based on 39 Case-Control Studies
title_full_unstemmed PARP-1 Val762Ala Polymorphism and Risk of Cancer: A Meta-Analysis Based on 39 Case-Control Studies
title_short PARP-1 Val762Ala Polymorphism and Risk of Cancer: A Meta-Analysis Based on 39 Case-Control Studies
title_sort parp-1 val762ala polymorphism and risk of cancer: a meta-analysis based on 39 case-control studies
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4031170/
https://www.ncbi.nlm.nih.gov/pubmed/24853559
http://dx.doi.org/10.1371/journal.pone.0098022
work_keys_str_mv AT qinqin parp1val762alapolymorphismandriskofcancerametaanalysisbasedon39casecontrolstudies
AT lujing parp1val762alapolymorphismandriskofcancerametaanalysisbasedon39casecontrolstudies
AT zhuhongcheng parp1val762alapolymorphismandriskofcancerametaanalysisbasedon39casecontrolstudies
AT xuliping parp1val762alapolymorphismandriskofcancerametaanalysisbasedon39casecontrolstudies
AT chenghongyan parp1val762alapolymorphismandriskofcancerametaanalysisbasedon39casecontrolstudies
AT zhanliangliang parp1val762alapolymorphismandriskofcancerametaanalysisbasedon39casecontrolstudies
AT yangxi parp1val762alapolymorphismandriskofcancerametaanalysisbasedon39casecontrolstudies
AT zhangchi parp1val762alapolymorphismandriskofcancerametaanalysisbasedon39casecontrolstudies
AT sunxinchen parp1val762alapolymorphismandriskofcancerametaanalysisbasedon39casecontrolstudies